REN and hypertensive disorder: Sacubitril/valsartan was proven to be superior in reducing left ventricular hypertrophy because it targets both the renin–angiotensin system and neprilysin, and thus this therapy has an advantageous cardiovascular prognosis in patients with hypertension compared with unitary treatment using olmesartan (Schmieder et al., 2017).